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Background: The potential for Bacillus Calmette-Guérin (BCG) vaccination to protect infants against non-mycobacterial
disease has been suggested by a randomised controlled trial conducted in low birth-weight infants in West Africa.
Trials to confirm these findings in healthy term infants, and in a non-West African setting, have not yet been carried
out. In addition, a biological mechanism to explain such heterologous effects of BCG in the neonatal period has not
been confirmed. This trial aims to address these issues by evaluating whether BCG non-specifically enhances the innate
immune system in term Ugandan neonates, leading to increased protection from a variety of infectious diseases.
Methods: This trial will be an investigator-blinded, randomised controlled trial of 560 Ugandan neonates, comparing
those receiving BCG at birth with those receiving BCG at 6 weeks of age. This design allows comparison of outcomes
between BCG-vaccinated and -naïve infants until 6 weeks of age, and between early and delayed BCG-vaccinated
infants from 6 weeks of age onwards. The primary outcomes of the study will be a panel of innate immune parameters.
Secondary outcomes will include clinical illness measures.
Discussion: Investigation of the possible broadly protective effects of neonatal BCG immunisation, and the optimal
vaccination timing to produce these effects, could have profound implications for public healthcare policy. Evidence of
protection against heterologous pathogens would underscore the importance of prioritising BCG administration in a
timely manner for all infants, provide advocacy against the termination of BCG’s use and support novel anti-tuberculous
vaccine strategies that would safeguard such beneficial effects.
Trial registration: ISRCTN59683017: registration date: 15 January 2014
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Background and rationale
Bacillus Calmette-Guérin (BCG) immunisation, the only
currently available tuberculosis (TB) vaccine, is one of
the most frequently administered immunisations world-
wide with more than 100 million children receiving
it per year [1]. Although it provides protection against* Correspondence: Sarah.prentice@lshtm.ac.uk
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unless otherwise stated.severe forms of TB in children, it has variable efficacy
against adult pulmonary disease, with protection gene-
rally poor in high-risk areas such as sub-Saharan Africa
and Asia [2]. There are currently concerted efforts in the
scientific community to improve anti-TB protection
either by enhancing existing BCG immunisation stra-
tegies or by developing an alternative vaccine [3].
However, it has been suggested that BCG may protect
infants against a variety of non-mycobacterial pathogens
and thus have beneficial effects beyond protection
against TB [4]. The evidence for such a ‘non-specific’
effect of BCG is currently in equipoise. It is, therefore,
important and pressing to interrogate this possibilityl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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be evaluated in terms of overall benefit to recipient, ra-
ther than in terms of TB-specific protection alone.
The possibility that BCG may have non-specific bene-
ficial effects on diseases other than TB has been a con-
troversial and highly-debated subject. Observations that
BCG may have a greater impact on mortality than can
be explained by protection against TB were first made
following its introduction more than 80 years ago. Stu-
dies including more than 46,500 infants, carried out in
the 1940s and 1950s in the USA and UK, showed on
average a 25% (95% CI 6 to 41%) reduction in all cause
mortality in children receiving BCG compared to those
not receiving it [5-9]. This reduction was noted at the
time to be larger than could be attributed to the ex-
pected reduction in rates of TB. However, as many of
these studies were not strictly randomised or controlled,
and this was a period of major public health improve-
ments, the results were assumed to result from confoun-
ding effects. Similar arguments have been used to dismiss
a number of observational studies carried out more re-
cently, in Guinea-Bissau, which appear to show that in-
fants who receive BCG at birth have lower all-cause
morbidity and mortality than infants who do not [10-17].
Good quality, randomised controlled trials evaluating
the possibility of non-specific effects of BCG are ex-
tremely limited. Only one trial has been conducted to
specifically evaluate non-tuberculous mortality as a re-
sult of altered BCG vaccination schedule [18]. In this
trial of low birth-weight infants in Guinea-Bissau, sub-
jects randomised to receive BCG at birth had a 45%
lower mortality rate (MRR 0.55 (0.34 to 0.89)) in the first
2 months of life than infants who had BCG immunisa-
tion delayed to, on average, 6 weeks of age. The reduc-
tion in deaths was due to protection from all-cause
febrile illness, respiratory tract infections and diarrhoea,
but not against TB (verbal autopsy data). However,
although this study is the only trial designed primarily to
investigate the impact of BCG on all-cause mortality, nine
other randomised controlled trials have been conducted
that delayed BCG vaccination past the neonatal period in
high mortality areas [19-27]. None of these studies re-
ported significant differences in mortality, either during
the period when one intervention group had received
BCG and the other group had not, or subsequently. Also,
in contrast to the Guinea-Bissau trial, three large cohort
studies appear to show that infants who receive BCG vac-
cination at the same time as Diphtheria Tetanus Pertussis
(DTP) vaccination (at 6 weeks of age) have reduced
longer-term all-cause mortality than those that have re-
ceived BCG at birth [28]. Thus, it is currently unclear
whether BCG has non-specific beneficial protective effects
against diseases other than TB, and if so, what timing of
administration would be optimal to induce these effects.The possibility that BCG may have effects against
non-tuberculous disease has also had limited acceptance
in the scientific and public health communities due to
the lack of a confirmed biological mechanism. Investiga-
tions into the hypothesis that BCG immunisation might
skew the adaptive immune response from the T-helper
type 2 (Th2) dominant environment of early neonatal
life, toward a more protective T-helper type 1 (Th1) en-
vironment, have been inconclusive [29-32]. The evidence
from the Guinea-Bissau randomised controlled trial,
however, shows that any putative immunological mech-
anism would need to be: 1) effective at birth despite the
immature neonatal immune system, 2) rapidly inducible
(most protection at < 1 week post-immunisation) and 3)
active against a range of pathogens. These features
would suggest that BCG mediates its non-specific effects
by stimulating the innate immune system. This is the
hypothesis that we aim to interrogate during this study.
We plan to investigate three different aspects of the
innate immune system. Firstly, we will investigate whe-
ther non-specific pro-inflammatory cytokine production
is enhanced in infants who have received BCG by using
in vitro stimulation with non-mycobacterial stimulants.
Few studies exist investigating alterations in cytokine
production to heterologous stimulants following neo-
natal BCG immunisation [33-35]. The few that have
been reported have focused on adaptive cytokines, using
a 6-day in vitro stimulation protocol, which is sub-
optimal for the quantification of innate cytokine produc-
tion. No studies exist where samples have been collected
prior to 5 months of age, thus early non-specific effects
of BCG will have been missed. Lastly, in vitro stimulants
used in previous studies have been antigens (for ex-
ample, lipopolysaccharide or tetanus toxoid) and not
whole organisms, potentially excluding the effect of
other important pattern recognition receptor pathways.
As part of this proposed study we aim to address these
issues by focusing on the impact of BCG on innate cyto-
kine production, conducting overnight stimulation using
non-mycobacterial whole organism stimulants, and by
using blood samples taken before 10 weeks of age.
Secondly, we will investigate whether BCG might me-
diate any non-specific beneficial effects by inducing a
plasma hypoferraemia. Iron supply is critical for the
virulence of most pathogens [36], with plasma hypofer-
raemia profoundly inhibiting the growth of bacteria
[37,38], viruses [39], protozoa [40-43] and fungi [44,45].
As part of the innate acute-phase response, plasma
hypoferraemia is induced by IL-6-driven release of hep-
cidin. Guinea pig models reveal that BCG also induces a
rapid bacteriostatic hypoferraemia [46], although in-
volvement of the IL-6/hepcidin pathway has never been
studied. To our knowledge, no studies exist investigating
the influence of BCG immunisation on the human iron-
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tigate whether BCG immunisation in neonates induces al-
terations to the inflammatory iron axis, as a potential
effector mechanism for heterologous protection.
Lastly we will investigate whether BCG induces epi-
genetic modification at the promoter region of pro-
inflammatory cytokines in monocytes, thereby providing a
mechanism for ‘training’ the innate immune system to re-
spond in a persistently amplified manner to challenge by
non-mycobacterial pathogens. BCG immunisation of
naïve adults has been shown to produce trimethylation
of histone-3 lysine 4 (H3K4) at the promoter region of
TNF-α, IL-1β and IFN-γ in monocytes [47]. This led to
enhanced cytokine production following in vitro stimulation
with the heterologous pathogens Staphylococcus aureus
(S. aureus), Streptococcus pneumonia (S. pneumoniae) and
Candida albicans (C. albicans), which persisted to at least
3 months post-immunisation. We will investigate whether
BCG immunisation produces similar epigenetic modifica-
tion of monocytes in neonates.
Thus, we have designed a randomised controlled trial,
comparing BCG administration at birth with administra-
tion at 6 weeks of age in healthy Ugandan neonates. We
will use this to interrogate the impact of BCG vacci-
nation on the innate immune response, as well on all-
cause clinical illness outcomes. We believe this study
will add significantly to the current debate regarding the
non-specific effects of BCG vaccination as it aims to
confirm a biological mechanism to explain such effects.
Also, by being conducted in healthy neonates, in a geo-
graphical location distant from previous studies and by
an independent research group, it will help to under-
stand the global applicability of any non-specific effects.
Aims and objectives
The aims of our study are as follow:
1. To determine whether BCG immunisation at birth
alters the innate immune response to heterologous
pathogens in the short term (within 1 week)
2. To determine whether BCG immunisation at birth
alters the innate immune response to heterologous
pathogens in the longer term (at 6 weeks)
3. To determine whether BCG immunisation given at
age 6 weeks has similar short- and longer-term
effects on the innate immune response to
heterologous pathogens compared to BCG
immunisation at birth
4. To obtain data upon the effect of BCG on neonatal
susceptibility to invasive infections in Ugandan
infants
Aims 1, 2 and 3 will be addressed using sub-studies to
interrogate 3 different elements of the innate immunesystem. The individual objectives for these studies are
shown in Table 1. Clinical outcome measures from all 3
sub-studies will be combined to address Aim 4.
Study design
This study is an investigator-blinded randomised con-
trolled trial of BCG vaccination given at birth versus
BCG vaccination given at 6 weeks of age. Cord blood
and two venous blood samples will be collected from
participants to allow comparison of innate immune
system parameters. All participants will be clinically
followed-up until 10 completed weeks of age, to allow
comparison of illness outcomes. This study design will
allow comparison of outcomes between BCG-naïve and
-vaccinated infants up to 6 weeks of age, and early with
delayed BCG-vaccinated infants from 6 to 10 weeks of
age, helping to identify whether there is a critical period
for BCG-induced non-specific effects. The time-point of
6 weeks for the delayed BCG group has been chosen as
it is the longest delay possible prior to the potential con-
founding influence of primary immunisations.
Methods
Setting and participants
Infants will be recruited on the day of birth from the ma-
ternity ward of Entebbe Grade B hospital, a government
hospital located in Wakiso District in central Uganda. The
region is populated mainly by semi-urban, rural and
fishing communities. Neonatal mortality rates in Uganda
remain high at 28/1,000 live births, with a large propor-
tion attributable to invasive infectious diseases.
Eligibility criteria
The inclusion criteria for this study are:
1) Infant of a gestational age and birth weight sufficient
to allow discharge directly home from hospital
without requirement for supplemental oxygen
or feeding
2) Delivery sufficiently uncomplicated to allow
discharge directly from hospital without inpatient
management
3) HIV-negative mother (based on antenatal records)
4) Residence within the study catchment area
5) Consenting mother
No specific weight or gestational age limit has been set
for this study. Clinical responses to early BCG are sug-
gested to have the greatest effect in infants of the lowest
birth weight [18]; thus, it is important to include these
infants in data collection. No increased rate of detrimen-
tal side-effects or reduction of immunological efficacy
has been shown with BCG immunisation of premature
infants [48]. Written informed consent will be obtained
Table 1 Objectives for immunological sub-studies
Sub-study Primary objectives Secondary objectives
Cytokine sub-study Cross-sectional comparison of IL-1β, IL-6, TNF-α and IFN-γ
cytokine levels following overnight in-vitro stimulation
with S. aureus, S. pneumoniae, E. coli, C. albicans and
Poly I:C/CpG between the two intervention groups:
Longitudinal analysis of within-infant changes in innate
cytokine production following in-vitro stimulation with
S. aureus, S. pneumoniae, E. coli, C. albicans and Poly I:C/CpG.
1. Shortly after birth intervention (BCG vaccination/
no vaccination): Aim 1
2. Six weeks post-birth intervention (immediately prior to
first dose of primary vaccination): Aim 2
3. Shortly after 6-week intervention (BCG vaccination/
no vaccination): Aim 3
4. Three weeks post-6-week intervention (immediately prior
to second dose of primary vaccinations): Aim 3
Iron sub-study Cross-sectional comparison of transferrin saturation and
hepcidin levels between the two intervention groups:
Cross-sectional comparison of serum iron, total iron
binding capacity, ferritin, transferrin, haemoglobin and
red cell parameters at the above time-points.
1. Shortly after birth intervention (BCG vaccination/no
vaccination): Aim 1
Longitudinal analysis of within-infant changes to iron status
following in-vivo non- specific stimulation (provided by
primary vaccinations)
2. Six weeks post-birth intervention (shortly after first dose
of primary vaccination): Aim 2
3. Shortly after 6-week intervention (BCG vaccination/
no vaccination): Aim 3
4. Three weeks post-6-weeks intervention (shortly after
second dose of primary vaccination): Aim 3
Epigenetic sub-study Cross-sectional comparison of monocyte histone-3 lysine 4
trimethylation (H3K4me3) at the promoter region of pro-
inflammatory cytokines between the 2 intervention groups:
Longitudinal analysis of within-infant changes in monocyte
epigenetic modification.
1. Shortly after birth intervention (BCG vaccination/
no vaccination): Aim 1
2. Six weeks post-birth intervention (immediately prior to
first dose of primary vaccination): Aim 2
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in the study.
Neonates will be excluded from the study if:
1) Cord blood is not obtained
2) They have major congenital malformations
3) The infant is clinically unwell, as judged by a
midwife
4) Known maternal TB or active TB within the family
(based on direct questioning of mother during
recruitment)
5) Maternal or family member positive for any of the
following TB screening symptoms:
 Cough > 2 weeks
 Recent haemoptysis
 >3 kg weight loss in past month
 Recurrent fevers/chills or night sweats for the
past 3 days or moreIntervention and randomisation
All infants will receive 0.05 ml of BCG-Statens Serum
Institute (SSI, Copenhagen, Denmark) (Danish Strain
1331) intra-dermally into the right deltoid. This will begiven either at birth (Early intervention arm) or at
6 weeks of age (Delayed intervention arm).
Intervention and blood sampling time-point allocation
will be determined by block randomisation, stratified by
sex. This will be carried out by an independent sta-
tistician, prior to the trial commencement, using Stata
(StataCorp, College Station, TX, USA) to generate the
allocation sequence. Allocations will be concealed within
sequentially numbered, sealed opaque envelopes, pre-
pared by two research assistants who are independent of
the trial. Upon delivery of an eligible infant, assignment
of allocation will be carried out by midwives who will
select the next sequential envelope according to the
infant’s gender.
Blinding
This study will be single blind. Mothers will not be
blinded to intervention allocation due to lack of feasi-
bility (BCG produces a visible reaction) and to reduce
confusion if a child who is lost to follow-up presents to
a community immunisation clinic.
Staff involved in administering BCG immunisation to
the participants, either at birth or at 6 weeks of age, will
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outcomes.
Investigators performing clinical assessment of chil-
dren will be blinded to intervention allocation by means
of a plaster placed over the area corresponding to BCG
vaccination site. This will be placed by a nurse not in-
volved in clinical assessment, prior to physician assess-
ment. If a child is presenting due to concerns about the
immunisation site it will be left uncovered and the un-
blinding documented. Illness events arising from concerns
or complications directly related to the BCG immunisa-
tion will not be included in the analysis of illness events,
but will be presented separately.
Immunological investigations will be conducted on
blood samples identified only by study number. The
intervention allocation code will only be broken once




Figure 1 shows the SPIRIT (Standard Protocol Items:
Recommendations for Interventional Trials) diagram for
the trial procedures. On presentation to labour ward,
mothers in active labour will be screened for their eli-
gibility and informed consent will be taken. Following
delivery the infant will be assessed for eligibility and pla-
cental cord blood collected. Infants who are eligible for
the study will be randomised as described above, to re-
ceive BCG vaccination either immediately or at 6 weeks
of age. All infants will be followed-up until 10 completed
weeks of age. During this time 2 × 2 ml venous blood sam-
ples and 2 stool samples will be collected and all routine
immunisations will be given (Oral Polio Vaccination
(OPV) at birth and primary immunisations at 6 and
10 weeks of age). Clinical follow-up of the infants will be
carried out by weekly telephone interviews to check the
well-being of participants, and physician review and an-
thropometry at each routine clinic visit for blood samples/
routine immunisations (on average four visits per
participant). Unwell participants presenting to the study
clinic or Entebbe Grade B hospital will also be reviewed
and managed by the study team, free of charge. Study
follow-up is complete once the child has completed
10 weeks of age.
Consent
Sensitisation of parents to the study will occur during
antenatal classes via posters, group discussions and dur-
ing individual midwife-led consultations. Mothers will
then be approached for consent by trained midwives
when presenting in active labour to Entebbe Grade B
hospital. The study will be explained in detail verbally
and the information sheet provided (or read to illiteratemothers). Information sheets will be available in English
and Luganda. Consent will also be taken to allow for
storage of excess samples and use of data in future re-
search studies. Although consent during labour is not
optimal, it is necessary to enable cord blood collection.
However, consent will be verbally reconfirmed with
mothers following delivery prior to any intervention. This
method of consent and recruitment has been piloted in
the same hospital and shown to be an appropriate and
successful method.
Data collected
Demographic details, anthropometric measurements and
socio-economic indices will be collected at enrolment in-
cluding gender, gestational age, birth weight, occipito-
frontal circumference and length, maternal age and parity,
parental ethnicity, parental educational level attained, ac-
commodation type and assets. Global Positioning System
(GPS) co-ordinates of the participant’s home address will
also be collected to aid follow-up.
During routine clinic visits anthropometric and vital
sign measurements will be collected. All mothers will be
interviewed about illness episodes in the participant since
they were last seen in clinic and any current concerns.
Physical examination findings will be documented.
A standardised illness episode case report form will be
completed whenever a child presents unwell to the
research clinic or paediatric ward at Entebbe Grade B
hospital. This will include anthropometric and vital sign
measurement, symptoms and signs, investigation results,
final diagnosis and outcome.
All participants will be interviewed by telephone on a
weekly basis by a fieldworker using a standardised case re-
port form to ensure the health of the infant. Any infants
for whom there are concerns will be reviewed in clinic.
This intensive follow-up will enhance identification of
clinical illness episodes, which are secondary outcomes for
the study. More importantly, however, it will allow early
identification and management of any cases of perinatal
TB, particularly in the delayed intervention group. Any
suspected or confirmed cases of TB occurring during the
study will be reported to the ethics committees and Data
Safety Monitoring Board (DSMB), who will decide
whether the study needs to be stopped early for safety.
Direct electronic data entry will occur for all case
report forms. This will be verified and optimized by
co-documentation with paper case report forms at the
beginning of the study. Data will be maintained in
encrypted, password protected forms, to maintain
confidentiality.
Blood samples collected
All participants in the study will have 10 ml placental
cord blood collected at birth; divided into 5 ml of
Figure 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) diagram of study procedures.
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(EDTA)-anticoagulated blood. They will then have 2-ml
venous blood samples collected at 2 time-points between
birth and their exit from the study at 10 completedweeks of age. Each sub-study has up to four possible
time-points where blood samples are collected, but each
infant will only be bled at two of these time-points
(randomly allocated) to avoid undue stress for the baby
Prentice et al. Trials  (2015) 16:149 Page 7 of 12and the mother. The time-points have been selected to
enable interrogation of the changes to the innate im-
mune system induced by BCG both acutely following
vaccination and in the longer term. The timing of the
blood samples in the iron sub-study differs slightly from
those in the cytokine and epigenetic sub-studies (see
Table 2). These differences are necessitated by the
systemic nature of iron metabolism. As hepcidin is pro-
duced mainly in the liver this precludes analysis of iron
metabolism following in-vitro non-specific stimulation.
Thus, the iron sub-study will use routine primary immu-
nisations as in-vivo non-specific stimuli and measure the
resulting changes to iron parameters.
Stool samples
Stool samples will be collected at the 6-week and 10-week
time-points and stored to allow for future analysis, fun-
ding permitting.
Other samples collected
Whenever an unwell participant presents to the study
team investigations and treatments will be conducted as
directed by the attending clinician. Investigations will in-
clude cultures for accurate diagnosis of febrile illness.
An extra 2-ml blood sample will be taken from any par-
ticipant under-going phlebotomy provided that this will
not compromise the child’s health or well-being. This
will allow a sub-study to be conducted to compare pri-
mary immunological outcomes in unwell children ac-
cording to BCG status.
Laboratory procedures
Cytokine sub-study
Overnight whole blood stimulation with the non-specific
stimulants S. aureus, S. pneumoniae, E. coli, C. albicans
and polyinosinic:polycytidylic acid/C-phosphate-G (Poly I:
C/CpG) will be carried out using fresh sodium-heparinised
blood. Measurement of the pro-inflammatory cytokines
IL-1β, IL-6, TNF-α and IFN-γ by ELISA (BD-OptEIA,
Becton, Dickinson and Company, Oxford, UK) will then
be conducted on the harvested supernatant following stor-
age at −80°C. These stimulants have been chosen because
they are the most common pathogens isolated from septicTable 2 Blood sample time-points (T) according to immunolo
Blood sample T1
(first week of life)
Blood T2 (6 wee
Cytokine sub-study 5 days after birth Immediately befo
immunisations
Iron sub-study 5 days after birth 1 day after prima
immunisations
Epigenetic sub-study 5 days after birth Immediately befo
immunisationsneonates in Uganda [49] and because they represent a range
of pathogen types and toll-like receptor pathways.
Epigenetic sub-study
The levels of trimethylation of H3K4 at the promoter re-
gion of pro-inflammatory cytokines will be assessed using
chromatin immunoprecipitation followed by qPCR. Peri-
pheral blood mononuclear cell (PBMC) isolation for this
work will occur by density-centrifugation over histopaque
(Sigma-Aldrich, Dorset, UK).
Iron sub-study
Measures of iron status will be conducted on the plasma
fraction of lithium-heparinised blood following storage
at −80°C. Serum iron, Unbound Iron Binding Capacity
(UIBC), Total Iron Binding Capacity (TIBC), Transferrin
Saturation (TSAT) and ferritin will be measured using the
automated Cobas Integra (Roche Diagnostics, Switzerland).
The hormone hepcidin will be quantified using ELISA
(Bachem-25, Bachem, Switzerland).
Red cell parameters will be measured from fresh
EDTA whole blood using a Coulter AC.T 5 Diff CP hae-
matology analyser (Beckman Coulter, Inc, CA, USA).
Primary outcomes
Cytokine sub-study
 IL-1β, IL-6, IL-10, TNF-α and IFN-γ cytokine
levels following in-vitro stimulation with S. aureus,
S. pneumoniae, E. coli, C. albicans and Poly I:C/CPG.
Epigenetic sub-study
 H3K4 trimethylation at the region of





Primary outcomes in each sub-study will be compared
between the 2 intervention groups both acutely followinggical sub-study
ks of age) Blood sample T3
(6 weeks of age)
Blood sample T4
(10 weeks of age)




ry 5 days after primary
immunisations
1 day after primary
immunisations
re primary
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time-points distant from vaccination (6 and 10 weeks
of age).
Secondary outcomes
 Physician-diagnosed infectious disease
 Parental-reported infectious disease
 Culture-positive infectious disease
 Mortality
The above clinical outcomes for the three sub-studies
will be analysed together to increase power.







 Red cell parameters
In a secondary analysis, longitudinal within-infant
changes in primary outcomes will also be analysed for
each sub-study.
Sample size considerations
Each sub-study is powered for its own primary out-
comes. The overall sample size is the summation of the
participants required for each sub-study.
Cytokine sub-study: n = 240
Due to paucity of published data in this area, an ap-
proach based on standard deviation (SD) difference in
average population cytokine levels has been used. Forty-
eight subjects per intervention group (BCG immunisa-
tion at birth or at 6 weeks of age) will be needed at each
time point to show a 0.66 SD difference in average
population cytokine levels with 90% power and 5% sig-
nificance. Sixty infants per intervention group per time
point will be recruited to allow for attrition. As each re-
cruited infant will be bled at 2 time-points, 240 infants
will be recruited in total to allow for the 4 time-points.
Epigenetic sub-study: n = 80
The only previous study in this area (which was per-
formed in adults) required 20 subjects per intervention
arm [47]. We will recruit 40 subjects to each interven-
tion arm to allow for attrition and also due to the re-
quirement for a full 2-ml blood sample for epigenetic
analysis, which is unlikely to be obtained for all subjects.
Due to funding constraints, epigenetic analysis will be
restricted to the first two sampling time-points, and eachinfant will be bled at both time-points, eighty subjects
will be recruited in total.
Iron sub-study: n = 240
Sample size determination was performed using TSAT
as it is the only primary outcome parameter currently
of clinical relevance. Average neonatal TSAT in low-
income settings is 55% [50]. Fifty infants in each group
at each time point will be needed to show a 30% reduc-
tion in transferrin saturation (reduction to average TSAT
levels in low income settings) with 90% power and 5%
significance. Sixty subjects will be recruited to each
intervention group at each time point to allow for attri-
tion. As each recruited infant will be bled at 2 time-
points, 240 infants will be recruited in total.
Overall sample size: n = 560
Combined analysis of clinical end-points from all three
sub-studies will be conducted as secondary analysis.
Based on data from a previous study in Entebbe [51]
we expect 80% power to detect a ≥ 40% reduction in
physician-diagnosed invasive infections with 5% signifi-
cance. The effect of BCG is unlikely to be this pro-
nounced, but this preliminary data combined with the
primary immunological outcomes, should provide suffi-
cient evidence to determine whether expanding the co-
hort would be valuable.
Data management
Description of the data
This is a randomised controlled trial with datasets gen-
erated from clinical questionnaires and laboratory assays.
A combination of direct electronic capture and paper
forms will be used, linked by a unique participant iden-
tifier. Microsoft Access (Redmond, WA, USA) will be
utilised to produce the study database. Data will be
exported from Microsoft Access to Stata (StataCorp,
College Station, TX, USA) for statistical analysis.
Quality assurance
A detailed data dictionary with range checks will be used
to reduce data entry errors. Quality control checks will
be run by the data clerk, on a weekly basis, who will
highlight any queries to the principal investigator. Data
will only be uploaded onto the master database once any
queries highlighted by quality control checks have been
resolved.
Statistical analysis
Group characteristics will be compared using Pearson’s
Chi-squared test for categorical variables and the t-test
for continuous variables. Cross-sectional comparisons
between intervention groups at each time-point will be
carried-out using the t-test for differences between
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log-transformed before analysis; Mann–Whitney two-
tailed test will be used for persistently skewed data. If
potential confounders remain unbalanced between the
groups despite randomisation: for instance season of
birth, these will be adjusted for using multiple linear
regression analysis. Paired/longitudinal analysis of within
infant changes in parameters over time will be con-
ducted using the paired student t-test or Wilcoxon
matched-pairs test. Incidence rate of invasive infectious
disease in the first 10 weeks of life will be compared by
Poisson regression with a random effects model to allow
for within-child clustering. Statistical significance will be
assessed at the 2-sided 0.05 level but interpretation of
results will not be solely reliant on P-values.
Trial monitoring
This clinical trial will be conducted according to Good
Clinical Practice standards. An internal study monitor
will oversee the day-to-day running of the trial locally,
with external oversight and monitoring co-ordinated by
the London School of Hygiene and Tropical Medicine.
This may include internal audit by the Clinical Trials
Quality Assurance Manager and external audits by a
third party. A Trial Steering Committee (TSC) and an
independent DSMB have been set up for this study. The
DSMB will look at a number of clinical outcome mea-
sures, documented in 'real time' during the study, to assess
whether the study needs to be stopped early for safety.
Safety reporting for this trial will follow standard
Uganda Virus Research Institute and London School of
Hygiene and Tropical Medicine procedures. This in-
cludes notification of Serious Adverse Events (SAEs) to
the local ethics committee within 24 hours, notification
of Suspected Unexpected Serious Adverse Reactions
(SUSARs) to the sponsor within 7 days if life-threatening
or 15 days if non-life-threatening. The manufacturer of
the BCG vaccine, Staten Serum Institute, will also be no-
tified of any SAE/SUSAR.
Ethics
As this trial will alter the timing of BCG from the
current Ugandan guidelines (BCG at birth) in half of
the study infants, a thorough risk-benefit analysis of a
6-week delay in vaccination has been conducted. In
summary, we feel that the risks of delay are minimal for
the following reasons:
 Neonatal TB is rare and the chances of infants in
the delayed BCG arm becoming infected during a
6-week delay period are extremely small. At least 7
previous studies have been conducted in areas of
high TB prevalence that randomised infants to
delayed BCG vaccination past 6 weeks of age [19-24].None of these studies showed an increase in TB
incidence in the delayed vaccination group either in
the period prior to vaccination or during follow-up
(cumulative n for delayed BCG vaccination = 849,
median follow-up time 1 year).
 A recent study using an Entebbe based birth-cohort
showed a prevalence of latent TB infection of 9.7%
in children under 5 years old [52]. This suggests
that in our population, a 6-week delay in BCG
administration risks 0.63 infants becoming infected
with latent TB. However, the strongest risk factor
for latent TB acquisition in Entebbe is a known
contact with a TB case (odds ratio (OR) 2.62
(1.29 to 5.30), unpublished data). Thus, the
exclusion of infants at risk of TB from mother or a
household contact will reduce this risk to negligible.
Active weekly follow-up of infants will occur to
ensure they remain healthy and the trial will be
stopped early if cases of TB are found to be higher
in the delayed BCG arm.
There is also evidence that delay in BCG vaccination
from birth to 6 weeks may be beneficial for participants
because:
 The optimal timing of BCG vaccination for immunity
against TB is not known. There is some evidence that
delaying BCG past the neonatal period may improve
the magnitude and duration of anti-TB immunity,
thus providing direct benefit to participants in the
delayed vaccination arm [19-24].
 The incidence of vaccination-induced complications,
including BCG-induced abscesses, suppurative
lymphadenitis and osteomyelitis are reduced by
approximately one third in infants who receive
BCG vaccination after the neonatal period [21].
All infants in the study, whether in the early or delayed
BCG group will benefit from regular physician reviews and
free access to medical review and treatment if participants
become unwell. They will also benefit from receiving all
other primary vaccinations at the correct time as part of
the study. The most recent survey of vaccination rates in
Uganda showed that 56% of infants have not received their
first set of primary immunisations (diphtheria/tetanus/
pertussis/hepatitis B/Haemophilus influenzae (HiB) and
oral polio vaccine) by 12 weeks of age, with 26% still not
having received it by 1 year of age. This produces a substan-
tial risk for those children of contracting serious, prevent-
able illnesses, which participation in the study will negate.
Thus, we believe the general benefits of taking part in
the study will outweigh the extremely small risks from a
6-week delay in BCG vaccination. The full risk-benefit
analysis for this study can be found in Additional file 1.
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Uganda Virus Research Institute on AIDS (Ref: GC/127/
13/11/432), the Uganda National Council for Science
and Technology (Ref: HS 1524), The Office of the Presi-
dent of Uganda and the London School of Hygiene and
Tropical Medicine (Ref: 6545). This study will be con-
ducted according to the principles of the Declaration of
Helsinki.
Study limitations
The primary immunisation schedule imposes a number
of constraints on the design of this study, as blood sam-
ples need to be timed to limit the potentially con-
founding influence of non-BCG vaccinations on innate
immune responses. This is particularly relevant for com-
parison of the longer-term non-specific effects of BCG
between the Early and Delayed intervention arms at
10 weeks, where BCG will have been given more re-
cently in the Delayed intervention arm. As we are
investigating the acute response to non-tuberculous
stimulants, we believe that this should not be a problem,
as any bystander effect of BCG vaccination itself is likely
to be lost by 4 weeks of age. However, we are actively
seeking funding for a longer-term follow-up time-point
that should help to clarify this issue as well as to provide
information about the duration of any non-specific ef-
fects of BCG vaccination on the innate immune system.
Although it is important to understand the biological
mechanism underlying any non-specific effects of BCG
vaccination, ultimately the impact on all-cause clinical
illness episodes and mortality will be the outcome mea-
sures that are likely to have impacts on public healthcare
policy. This study has limited power to detect differences
in such outcomes, due to its small sample size. However,
if suggested by the immunological and preliminary cli-
nical data in this study, additional funding will be sought
to expand the cohort to allow full interrogation of cli-
nical outcomes.
Discussion
Global acceptance of the hypothesis that BCG immun-
isation affords non-specific protective effect when given
during infancy has been limited due to paucity of rando-
mised controlled trial data and because of a lack of a
confirmed biological mechanism to explain such effects
in the neonatal period. We aim to address these issues
by carrying out this randomised controlled trial in
Uganda, providing variety of location and research group
from much of the previous work, and investigating the
impact of BCG immunisation on the innate immune sys-
tem in neonates. Interrogation of the possible heterol-
ogous protection afforded by BCG immunisation, and
the optimal timing of immunisation to achieve beneficial
effects, is important to ensure that any new anti-TBvaccine or alteration in timing of BCG administration is
evaluated in terms of overall benefit to recipient, rather
than solely in terms of TB-specific protection alone.
Trial status
The study commenced recruitment in September 2014.
Two hundred and forty participants had been recruited
as of March 2015. The trial is projected to complete re-
cruitment by August 2015.
Additional file
Additional file 1: Risk-benefit analysis of altering BCG vaccination
from birth to 6 weeks of age.
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